COX-2 inhibitors - First, do no harm

New Zealand Medical Journal

Volumn 118, Issue 1211, 2005, Pages

  Weatherall, Mark ^a   Aldington, Sarah ^b   Shirtcliffe, Philippa ^b   Caldwell, Brent ^b   Beasley, Richard ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b MEDICAL RESEARCH INSTITUTE OF NEW ZEALAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; LUMIRACOXIB; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PLACEBO; PROSTACYCLIN; ROFECOXIB; THROMBOXANE A2; VALDECOXIB; LACTONE; PROSTAGLANDIN SYNTHASE INHIBITOR; SULFONE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLORECTAL ADENOMA; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; GASTROINTESTINAL DISEASE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; NEW ZEALAND; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; THROMBOCYTE AGGREGATION; THROMBOEMBOLISM; CHEMICALLY INDUCED DISORDER; DRUG CONTROL; RISK;

CARDIOVASCULAR DISEASES; CYCLOOXYGENASE INHIBITORS; DRUG AND NARCOTIC CONTROL; HUMANS; LACTONES; NEW ZEALAND; RISK; SULFONES;

EID: 21244495732     PISSN: 11758716     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Editorial

References (16)

1. Medsafe, New Zealand Medicines and Medical Devices Safety Authority. Hot topics: Medsafe advises review of all patients on COX-2 inhibitors; 2005. Available online. URL: http://www.medsafe.govt.nz/hot/COX2Fax.htm Accessed March 2005.
2. Andrew K. Arthritis drugs too risky - Medsafe. The Dominion Post, 23 February, 2005. Available online. URL: http://www.stuff.co.nz/stuff/0,2106,3196430a7144,00.html Accessed March 2005.
3. McAdam BF, Catella-Lawson F, Mardini IA, et al. Systematic biosynthesis of prosthcyclin to cyclooxygenase COX-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA. 1999;96:272-7.
4. Fitzgerald EA. Coxibs and cardiovascular disease. N Engl J Med. 2004;351:1709-11.
5. Juni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004;364:2021-9.
6. Bombadier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000; 343:1520-8.
7. Solomon SD, McMurray JJV, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352.
8. Ott E, Nussmeier NA, Duke PC, et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2003;125:1481-92.
9. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005;352 [Epub ahead of print].
10. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352 [Epub ahead of print].
11. New Ethicals Catalogue. Management of cardiovascular risk. Adis International 2003; May: 504-7.
12. Maxwell SR, Webb DJ. COX-2 selective inhibitors - important lessons learned. Lancet. 2005;365:449-51.
13. Psaty BM, Furberg CD. COX-2 inhibitors - Lessons in drug safety. N Engl J Med. 2005;352 [Epub ahead of print].
14. Topol EJ, Falk GW. A coxib a day wont keep the doctor away. Lancet. 2004;364:639-40.
15. European Medicines Agency. Updated questions and answers on COX-2 inhibitors. Available online. URL: http://www.emea.eu.int/pdfs/human/press/pr/6297805en.pdf Accessed March 2005.
16. Drazen JM. COX-2 inhibitors - A lesson in unexpected problems. N Engl J Med. 2005;352 [Epub ahead of print].